Alnylam Gross Profit from 2010 to 2024

ALNY Stock

USD 143.80 2.27 1.55%

Alnylam Pharmaceuticals Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Alnylam Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2003-03-31

Previous Quarter

666.2 M

Current Value

353.9 M

Quarterly Volatility

100.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 M, Interest Expense of 127.3 M or Other Operating Expenses of 2.2 B, as well as many exotic indicators such as Price To Sales Ratio of 12.42, Dividend Yield of 0.0 or Days Sales Outstanding of 60.78. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.

This module can also supplement Alnylam Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Alnylam Pharmaceuticals Technical models . Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Alnylam Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Alnylam Pharmaceuticals minus its cost of goods sold. It is profit before Alnylam Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Alnylam Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 868.6 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Alnylam Gross Profit Regression Statistics

	Arithmetic Mean	386,170,620
	Geometric Mean	108,768,266
	Coefficient Of Variation	140.15
	Mean Deviation	422,447,760
	Median	82,757,000
	Standard Deviation	541,220,142
	Sample Variance	292919.2T
	Range	1.6B
	R-Value	0.82
	Mean Square Error	102687.5T
	R-Squared	0.67
	Significance	0.0002
	Slope	99,389,775
	Total Sum of Squares	4100869.4T

Alnylam Gross Profit History

	2024	1.6 B
	2023	1.5 B
	2022	868.6 M
	2021	704.1 M
	2020	414.8 M
	2019	194.7 M
	2018	73.1 M

Other Fundumenentals of Alnylam Pharmaceuticals

Gross Profit Margin

Alnylam Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Intangible Assets	Net Receivables	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.1	0.6	-0.97	0.75	0.96	0.91	0.99	0.96	0.43	0.85	0.62	0.82	0.87	0.83	-0.13	0.98	-0.65	-0.58	0.77	-0.86	-0.89	0.47	0.92
Total Stockholder Equity	-0.1		-0.71	0.26	0.05	-0.11	-0.49	-0.08	-0.19	0.27	-0.56	0.26	-0.38	-0.52	0.28	1.0	-0.08	-0.46	0.12	-0.65	-0.12	0.38	-0.58	-0.45
Net Debt	0.6	-0.71		-0.71	0.27	0.67	0.81	0.58	0.7	0.05	0.83	0.13	0.86	0.85	0.21	-0.72	0.63	-0.03	-0.48	0.86	-0.46	-0.74	0.51	0.79
Retained Earnings	-0.97	0.26	-0.71		-0.77	-0.95	-0.96	-0.96	-0.98	-0.33	-0.92	-0.53	-0.88	-0.92	-0.78	0.29	-0.98	0.55	0.63	-0.85	0.85	0.96	-0.48	-0.96
Accounts Payable	0.75	0.05	0.27	-0.77		0.72	0.63	0.72	0.75	0.27	0.62	0.53	0.46	0.54	0.85	0.02	0.75	-0.6	-0.42	0.48	-0.72	-0.73	0.23	0.62
Short Term Investments	0.96	-0.11	0.67	-0.95	0.72		0.89	0.94	0.96	0.45	0.82	0.63	0.82	0.85	0.78	-0.14	0.96	-0.55	-0.71	0.73	-0.91	-0.87	0.44	0.9
Total Liab	0.91	-0.49	0.81	-0.96	0.63	0.89		0.9	0.91	0.27	0.97	0.43	0.87	0.97	0.61	-0.52	0.89	-0.38	-0.56	0.94	-0.7	-0.93	0.64	0.99
Total Current Assets	0.99	-0.08	0.58	-0.96	0.72	0.94	0.9		0.93	0.35	0.86	0.54	0.81	0.88	0.82	-0.12	0.97	-0.68	-0.54	0.79	-0.83	-0.86	0.51	0.9
Property Plant Equipment	0.96	-0.19	0.7	-0.98	0.75	0.96	0.91	0.93		0.42	0.85	0.63	0.9	0.87	0.77	-0.21	0.98	-0.52	-0.71	0.78	-0.9	-0.95	0.35	0.93
Current Deferred Revenue	0.43	0.27	0.05	-0.33	0.27	0.45	0.27	0.35	0.42		0.1	0.9	0.22	0.13	0.46	0.26	0.38	-0.25	-0.34	0.02	-0.41	-0.22	0.07	0.36
Long Term Debt	0.85	-0.56	0.83	-0.92	0.62	0.82	0.97	0.86	0.85	0.1		0.26	0.85	0.98	0.55	-0.58	0.84	-0.35	-0.48	0.98	-0.63	-0.9	0.68	0.95
Short Term Debt	0.62	0.26	0.13	-0.53	0.53	0.63	0.43	0.54	0.63	0.9	0.26		0.38	0.29	0.63	0.25	0.58	-0.33	-0.49	0.16	-0.63	-0.46	0.09	0.51
Intangible Assets	0.82	-0.38	0.86	-0.88	0.46	0.82	0.87	0.81	0.9	0.22	0.85	0.38		0.9	0.53	-0.4	0.87	-0.37	-0.6	0.84	-0.73	-0.89	0.33	0.88
Net Receivables	0.87	-0.52	0.85	-0.92	0.54	0.85	0.97	0.88	0.87	0.13	0.98	0.29	0.9		0.55	-0.54	0.87	-0.39	-0.5	0.97	-0.65	-0.89	0.66	0.95
Common Stock	0.83	0.28	0.21	-0.78	0.85	0.78	0.61	0.82	0.77	0.46	0.55	0.63	0.53	0.55		0.24	0.82	-0.82	-0.44	0.43	-0.79	-0.7	0.21	0.62
Net Tangible Assets	-0.13	1.0	-0.72	0.29	0.02	-0.14	-0.52	-0.12	-0.21	0.26	-0.58	0.25	-0.4	-0.54	0.24		-0.11	-0.41	0.13	-0.68	-0.1	0.41	-0.59	-0.48
Capital Surpluse	0.98	-0.08	0.63	-0.98	0.75	0.96	0.89	0.97	0.98	0.38	0.84	0.58	0.87	0.87	0.82	-0.11		-0.64	-0.63	0.77	-0.9	-0.91	0.36	0.9
Deferred Long Term Liab	-0.65	-0.46	-0.03	0.55	-0.6	-0.55	-0.38	-0.68	-0.52	-0.25	-0.35	-0.33	-0.37	-0.39	-0.82	-0.41	-0.64		0.1	-0.26	0.56	0.42	-0.07	-0.37
Long Term Investments	-0.58	0.12	-0.48	0.63	-0.42	-0.71	-0.56	-0.54	-0.71	-0.34	-0.48	-0.49	-0.6	-0.5	-0.44	0.13	-0.63	0.1		-0.42	0.84	0.67	-0.07	-0.59
Long Term Debt Total	0.77	-0.65	0.86	-0.85	0.48	0.73	0.94	0.79	0.78	0.02	0.98	0.16	0.84	0.97	0.43	-0.68	0.77	-0.26	-0.42		-0.52	-0.85	0.71	0.92
Short Long Term Debt	-0.86	-0.12	-0.46	0.85	-0.72	-0.91	-0.7	-0.83	-0.9	-0.41	-0.63	-0.63	-0.73	-0.65	-0.79	-0.1	-0.9	0.56	0.84	-0.52		0.8	-0.12	-0.73
Net Invested Capital	-0.89	0.38	-0.74	0.96	-0.73	-0.87	-0.93	-0.86	-0.95	-0.22	-0.9	-0.46	-0.89	-0.89	-0.7	0.41	-0.91	0.42	0.67	-0.85	0.8		-0.39	-0.93
Net Working Capital	0.47	-0.58	0.51	-0.48	0.23	0.44	0.64	0.51	0.35	0.07	0.68	0.09	0.33	0.66	0.21	-0.59	0.36	-0.07	-0.07	0.71	-0.12	-0.39		0.6
Capital Stock	0.92	-0.45	0.79	-0.96	0.62	0.9	0.99	0.9	0.93	0.36	0.95	0.51	0.88	0.95	0.62	-0.48	0.9	-0.37	-0.59	0.92	-0.73	-0.93	0.6

Click cells to compare fundamentals

About Alnylam Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Alnylam Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Alnylam Pharmaceuticals investors use historical funamental indicators, such as Alnylam Pharmaceuticals's Gross Profit, to determine how well the company is positioned to perform in the future. Although Alnylam Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Alnylam Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alnylam Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Alnylam Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	1.5 B	1.6 B
Gross Profit Margin	0.83	0.96

Pair Trading with Alnylam Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Alnylam Stock

0.87	LLY	Eli Lilly Earnings Call This Week	Pair Corr
0.78	VKTX	Viking Therapeutics Potential Growth	Pair Corr
0.72	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.6	NRSNW	NeuroSense Therapeutics	Pair Corr
0.59	XFOR	X4 Pharmaceuticals Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.

The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Alnylam Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alnylam Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alnylam Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alnylam Pharmaceuticals Stock:

How To Invest In Alnylam

Details

Is Alnylam Stock a good investment?

Details

What is Alnylam Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Alnylam Stock analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios

Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.52)

Revenue Per Share

14.637

Quarterly Revenue Growth

0.312

Return On Assets

(0.05)

Return On Equity

(15.01)

The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Gross Profit from 2010 to 2024

Latest Alnylam Pharmaceuticals' Gross Profit Growth Pattern

Alnylam Gross Profit Regression Statistics

Alnylam Gross Profit History

Other Fundumenentals of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Gross Profit component correlations

About Alnylam Pharmaceuticals Financial Statements

Pair Trading with Alnylam Pharmaceuticals

Moving against Alnylam Stock

Complementary Tools for Alnylam Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY